The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
Open accessAbstract
Nitrogen-containing bisphosphonates were shown to cause macrophage apoptosis by inhibiting enzymes in the biosynthetic pathway leading from mevalonate to cholesterol. This study suggests that, in osteoclasts, geranylgeranyl diphosphate, the substrate for prenylation of most GTP binding proteins, is likely to be the crucial intermediate affected by these bisphosphonates. We report that murine osteoclast formation in culture is inhibited by both lovastatin, an inhibitor of hydroxymethylglutaryl CoA reductase, and alendronate. Lovastatin effects are blocked fully by mevalonate and less effectively by geranylgeraniol whereas alendronate effects are blocked partially by mevalonate and more effectively by geranylgeraniol. Alendronate inhibition of bone resorption in mouse calvaria also is blocked by mevalonate whereas clodronate inhibition is not. Furthermore, rabbit osteoclast formation and activity also are inhibited by lovastatin and alendronate. The lovastatin effects are prevented by mevalonate or geranylgeraniol, and alendronate effects are prevented by geranylgeraniol. Farnesol and squalene are without effect. Signaling studies show that lovastatin and alendronate activate in purified osteoclasts a 34-kDa kinase. Lovastatin-mediated activation is blocked by mevalonate and geranylgeraniol whereas alendronate activation is blocked by geranylgeraniol. Together, these findings support the hypothesis that alendronate, acting directly on osteoclasts, inhibits a rate-limiting step in the cholesterol biosynthesis pathway, essential for osteoclast function. This inhibition is prevented by exogenous geranylgeraniol, probably required for prenylation of GTP binding proteins that control cytoskeletal reorganization, vesicular fusion, and apoptosis, processes involved in osteoclast activation and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Self-citationBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Self-citationSato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Self-citationBisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Self-citationGarrett, I. R., Boyce, B. F., Oreffo, R. O., Bonewald, L., Poser, J., & Mundy, G. R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114485 · Cited by 806
Kameshita, I., & Fujisawa, H. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90181-4 · Cited by 458
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Self-citationRemoval of Osteoclast Bone Resorption Products by Transcytosis
Salo, J., Lehenkari, P., Mulari, M., Metsikkö, K., & Väänänen, H. K. (1997) · Science · doi:10.1126/science.276.5310.270 · Cited by 430
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
GOTOH, Y., NISHIDA, E., YAMASHITA, T., HOSHI, M., KAWAKAMI, M., & SAKAI, H. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb19384.x · Cited by 376
Cited by
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,774
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Self-citationRauch, F., & Glorieux, F. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16051-0 · Cited by 1,167
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Self-citationInsulin signaling in osteoblasts integrates bone remodeling and energy metabolism
Ferron, M., Wei, J., Yoshizawa, T., Del Fattore, A., DePinho, R. A., Teti, A., Ducy, P., & Karsenty, G. (2010) · Cell · doi:10.1016/j.cell.2010.06.003 · Cited by 1,123
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Self-citationAlendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Self-citationBisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Self-citationThe Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035725 · Cited by 829
Kunzmann, V., Bauer, E., Feurle, J., Tony, F. W., & Wilhelm, M. (2000) · Blood · doi:10.1182/blood.v96.2.384 · Cited by 669
Calcium/Vitamin D Supplementation and Cardiovascular Events
Hsia, J., Heiss, G., Ren, H., Allison, M., Dolan, N. C., Greenland, P., Heckbert, S. R., Johnson, K. C., Manson, J. E., Sidney, S., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.673491 · Cited by 662
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Self-citationThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., Rogers, M. J., Russell, R. G. G., & Oppermann, U. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601643103 · Cited by 536
Self-citationBiochemical and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Crockett, J. C., Coxon, F. P., & Mönkkönen, J. (2011) · Bone · doi:10.1016/j.bone.2010.11.008 · Cited by 530
Self-citationBisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Self-citationFarnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1499 · Cited by 496
Inorganic pyrophosphate generation and disposition in pathophysiology
Terkeltaub, R. A. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.1.c1 · Cited by 484
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Self-citationThe role of bisphosphonates in breast cancer: Development of bisphosphonates
Fleisch, H. (2001) · Breast Cancer Research · doi:10.1186/bcr414 · Cited by 407
Bisphosphonate therapy for osteogenesis imperfecta
Dwan, K., Phillipi, C. A., Steiner, R. D., & Basel, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005088.pub4 · Cited by 405
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Self-citationOsteoblast proliferation and maturation by bisphosphonates
Im, G.-I., Qureshi, S. A., Kenney, J., Rubash, H. E., & Shanbhag, A. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.11.024 · Cited by 393
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Self-citationThe relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A.-M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A., Dunford, J. E., Barnett, B. L., Oppermann, U., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 391
Self-citationReciprocal Role of ERK and Nf-κb Pathways in Survival and Activation of Osteoclasts
Miyazaki, T., Katagiri, H., Kanegae, Y., Takayanagi, H., Sawada, Y., Yamamoto, A., Pando, M. P., Asano, T., Verma, I. M., Oda, H., et al. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.2.333 · Cited by 375
Becker, J., Semler, O., Gilissen, C., Li, Y., Bolz, H. J., Giunta, C., Bergmann, C., Rohrbach, M., Koerber, F., Zimmermann, K., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.01.015 · Cited by 362
Dr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Self-citationM-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401285 · Cited by 350
Self-citationJagdev, S. P., Coleman, R. E., Shipman, C. M., Rostami-H, A., & Croucher, P. I. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1727 · Cited by 346
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 333
Lehenkari, P. P., Kellinsalmi, M., Näpänkangas, J. P., Ylitalo, K. V., Mönkkönen, J., Rogers, M. J., Azhayev, A., Väänänen, H. K., & Hassinen, I. E. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12222-5 · Cited by 333
Self-citationOral statins and increased bone-mineral density in postmenopausal women
Edwards, C., Hart, D., & Spector, T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02408-9 · Cited by 326
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1451 · Cited by 314
Pharmacokinetics of Alendronate
Porras, A. G., Holland, S. D., & Gertz, B. J. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936050-00002 · Cited by 296
Ohtori, S., Inoue, G., Orita, S., Yamauchi, K., Eguchi, Y., Ochiai, N., Kishida, S., Kuniyoshi, K., Aoki, Y., Nakamura, J., et al. (2013) · Spine · doi:10.1097/brs.0b013e31828826dd · Cited by 293
Osteoporosis and Cardiovascular Disease: Brittle Bones and Boned Arteries, Is There a Link?
McFarlane, S. I., Muniyappa, R., Shin, J. J., Bahtiyar, G., & Sowers, J. R. (2004) · Endocrine · doi:10.1385/endo:23:1:01 · Cited by 289
von Knoch, F., Jaquiery, C., Kowalsky, M., Schaeren, S., Alabre, C., Martin, I., Rubash, H. E., & Shanbhag, A. S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.04.059 · Cited by 287
Sugiyama, M., Kodama, T., Konishi, K., Abe, K., Asami, S., & Oikawa, S. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2697 · Cited by 285
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity
Hanai, J.-I., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32741 · Cited by 281
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
Self-citationAlendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density
Bone, H. G. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.720 · Cited by 277
Frith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Self-citationCroucher, P. I., De Raeve, H., Perry, M. J., Hijzen, A., Shipman, C. M., Lippitt, J., Green, J., Van Marck, E., Van Camp, B., & Vanderkerken, K. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.482 · Cited by 266
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Finkelstein, J. S., Wyland, J. J., Lee, H., & Neer, R. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1703 · Cited by 265
Reszka, A. A., Halasy-Nagy, J. M., Masarachia, P. J., & Rodan, G. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34967 · Cited by 254
Self-citationRecent advances in understanding the mechanism of action of bisphosphonates
COXON, F., THOMPSON, K., & ROGERS, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 252
Self-citationInhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Halasy-Nagy, J. M., Rodan, G. A., & Reszka, A. A. (2001) · Bone · doi:10.1016/s8756-3282(01)00615-9 · Cited by 190
Self-citationIntracellular membrane trafficking in bone resorbing osteoclasts
Mulari, M., Vääräniemi, J., & Väänänen, H. K. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10371 · Cited by 104
Statins as modulators of bone formation
Edwards, C. J., & Spector, T. D. (2002) · Arthritis Research & Therapy · doi:10.1186/ar399 · Cited by 53
Use of bisphosphonates for the treatment of bone metastasis in experimental animal models.
Yoneda, T., Michigami, T., Yi, B., Williams, P. J., Niewolna, M., & Hiraga, T. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0133 · Cited by 52
Metadata
- Authors
- Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-01-05
- Volume
- 96
- Issue
- 1
- Pages
- 133-138
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1975107690
- Cited by
- 676
- References
- 22
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.